<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02918175</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00075572</org_study_id>
    <secondary_id>16SFRN30740010</secondary_id>
    <nct_id>NCT02918175</nct_id>
  </id_info>
  <brief_title>Mobile Health Behavioral Intervention in Patients With Heart Failure and Diabetes Mellitus</brief_title>
  <acronym>TARGET-HFDM</acronym>
  <official_title>Technology to Improve Drug Adherence and Reinforce Guideline Based Exercise Targets in Patients With Heart Failure and Diabetes Mellitus (TARGET-HFDM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this study is to test a personalized mHealth intervention designed
      to increase physical activity and improve medication adherence in subjects with heart failure
      and diabetes mellitus. The study will leverage consumer technology as both an intervention
      and as a tool for data collection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center randomized controlled study in eligible subjects with heart failure
      and diabetes mellitus. Step counts, self-reported quality of life, medication adherence,
      blood samples and relevant clinical measures will be collected from all study subjects. The
      mobile health (mHealth) intervention will combine personalized text messages to encourage
      physical activity and a medication adherence teaching tool. A total of approximately 200
      eligible subjects will be randomized in in a 1:1 ratio to either mHealth intervention + usual
      care/data collection or the control group (usual care/data collection only). The study
      duration is 6 months for all subjects; those in the intervention group will receive the
      mHealth intervention during the initial 3 months followed by 3 months of data collection
      only. The underlying hypotheses is that the proposed mHealth intervention can favorably
      impact specific health behaviors (physical activity and medication adherence) and physiologic
      measures of disease status for both heart failure and diabetes. Additional hypotheses to be
      tested will assess the persistence of behavioral changes (daily physical activity and
      medication adherence) and physiologic measures (NT-proBNP, HbA1c) beyond the 3-month time
      point of the active mHealth intervention (i.e. through 6 months).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2017</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean weekly step count</measure>
    <time_frame>from baseline to 3 months</time_frame>
    <description>Increased activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in medication adherence score</measure>
    <time_frame>from baseline to 3 and 6 months</time_frame>
    <description>Improved medication adherence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fill and refill performance rate</measure>
    <time_frame>from baseline to 3 and 6 months</time_frame>
    <description>Change in fill and refill performance rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean weekly step count</measure>
    <time_frame>from 3 to 6 months</time_frame>
    <description>Increased activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NT-proBNP levels</measure>
    <time_frame>from baseline to 3 to 6 months</time_frame>
    <description>biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1C levels</measure>
    <time_frame>from baseline to 3 to 6 months</time_frame>
    <description>biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score</measure>
    <time_frame>from baseline to 3 to 6 months</time_frame>
    <description>QOL</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in plasma metabolic profile</measure>
    <time_frame>from baseline to 3 months</time_frame>
    <description>biomarkers</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>mHealth Intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects in this study arm will have data on activity levels, quality of life, medication adherence, and blood samples collected. In addition, they will receive personalized feedback on activity goals based on prior week step counts and participate in coaching sessions using the Pillbox medication tool.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects in this study arm will have data on activity levels, quality of life, medication adherence, and blood samples collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>mHealth</intervention_name>
    <description>Personalized step count feedback and medication teaching tool.</description>
    <arm_group_label>mHealth Intervention</arm_group_label>
    <other_name>Feedback on step counts</other_name>
    <other_name>Duke PillBox medication adherence teaching tool</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥ 18 years of age

          -  Chronic heart failure, New York Heart Association (NYHA) class II-IV, with ongoing
             treatment with medications for heart failure for at least 1 month prior to enrollment

          -  Prior diabetes mellitus diagnosis, with ongoing treatment with anti-diabetes
             medications for at least 1 month prior to enrollment

          -  Adequate clinical stability in the judgment of the investigator to allow participation
             in study assessments and the intervention

          -  Independent with basic activities of daily living (ADLs), including the ability to
             ambulate independently

          -  No plan for revascularization (cardiac or peripheral), outpatient continuous
             intravenous inotrope administration, cardiac transplant or ventricular assist device
             implantation, or other cardiac surgery within 6 months of randomization

          -  Access to a compatible smart phone (iOS or Android)

          -  Signed informed consent

        Exclusion Criteria:

          -  Acute myocardial infarction within prior 4 weeks

          -  Already actively participating in formal, facility-based cardiac rehabilitation

          -  Severe stenotic valvular disease (e.g., severe aortic stenosis)

          -  Implanted left ventricular assist device (LVAD)

          -  Recipient of a heart transplant

          -  Terminal illness other than heart failure with life expectancy &lt; 6 months

          -  Impairment from stroke, injury or other medical disorder that precludes participation
             in the intervention

          -  Inability or unwillingness to comply with the study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary M Felker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Medical Center/Duke Clinical Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lori Hudson, PhD</last_name>
    <phone>919-668-8547</phone>
    <email>lori.hudson@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra Tourt-Uhlig, MSN</last_name>
    <phone>919-681-6757</phone>
    <email>tourt001@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jhina Patro</last_name>
      <email>jhina@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Dipanjan Banerjee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haley Dalzell</last_name>
      <phone>617-643-9245</phone>
      <email>hdalzell@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Maulik Majmudar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NewYork-Presbyterian Brooklyn Methodist Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Heitner, MD</last_name>
      <email>jfh9003@nyp.org</email>
    </contact>
    <investigator>
      <last_name>John Heitner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Wilson</last_name>
      <email>j.wilson@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Mentz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Health System</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22042-3300</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Cooper, MD</last_name>
      <email>Lauren.Cooper@inova.org</email>
    </contact>
    <investigator>
      <last_name>Lauren Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2016</study_first_submitted>
  <study_first_submitted_qc>September 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2016</study_first_posted>
  <last_update_submitted>November 28, 2017</last_update_submitted>
  <last_update_submitted_qc>November 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mHealth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

